| Cas No.: | 881188-51-8 |
| 名称: | (2S,5S,8R,14S)-5-(2-carboxyethyl)-14-((S)-2-formamido-4-(methylthio)butanamido)-2-isobutyl-8-(mercaptomethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazahexadecanedioic acid |
| 别名: | Foxy 5, Wnt5a peptide mimetic,FOXY-5,FOXY5 |
| SMILES: | [H]N([C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O)C(=O)[C@H](CCSC)NC=O |
| 分子式: | C26H42N6O12S2 |
| 分子量: | 694.77 |
| 纯度: | |
| 保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | |
| In Vivo: | |
| In Vitro: | |
| References: | Foxy-5 is a novel Wnt-5A mimicking hexapeptide that inhibits breast cancer metastasis in vivo by targeting cell motility; also significantly inhibits the initial metastatic dissemination of prostate cancer cells to regional and distal lymph nodes, specifically targets invasion without affecting apoptosis or viability of WNT5A-low prostate cancer cells. Breast CancerPhase 1 Clinical |
| Kinase Assay: | |
| Cell Assay: | |
| Animal Administration: | |
| References: |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
